Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Multiple Sclerosis With Copaxone and Albuterol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Patients may be eligible for this study if they:~* Have been diagnosed with RR-MS, within 2 years of diagnosis.~* Are 18-55 years old.~* Have RR-MS with evidence of demyelination on MRI scanning of the brain.~* Have extended disability status scale (EDSS) scores between 0 and 3.5.~* Have not taken Copaxone or oral myelin.~* Have not had immunomodulating therapy for the past 3 months.~* Have not taken immunosuppressants.~* Have not had steroid treatment 1 month before entry.~* Have no evidence of active infection or cancer.~Exclusion Criteria~Patients may not be eligible for this study if they:~* Have a normal brain MRI.~* Are not willing to practice contraception (applies to women who are able to have children).~* Are pregnant or breast-feeding.~* Are currently taking any of the following drugs: beta2-adrenergic agonist or antagonist, diuretics, tricyclic antidepressants, or monoamine oxidase inhibitors.~* Have heart, blood, liver, or kidney problems.~* Have a disease that affects blood clotting or lung function.~* Have abnormalities that relate to the endocrine system.~* Have a history of alcohol or drug abuse within 6 months of enrollment.~* Have been diagnosed with primary progressive MS, in which the disease slowly worsens without periods of recovery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive Copaxone and albuterol placebo
- 2 (Type: EXPERIMENTAL): Participants will receive Copaxone and albuterol

Based on this trial design, predict the completion outcome and termination type (if applicable).